First Biologic Approved in the EU for Gouty Arthritis - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

First Biologic Approved in the EU for Gouty Arthritis

ePT--the Electronic Newsletter of Pharmaceutical Technology

Ilaris (canakinumab), a selective, fully human, monoclonal antibody that inhibits interleukin-1 beta (IL-1 beta), has been approved in the EU for symptomatic pain relief in patients suffering from gouty arthritis whose condition cannot be managed with current treatments. Approval was supported by data from two Phase III trials, which demonstrated that patients treated with Ilaris experienced significantly greater pain relief compared to the injectable steroid triamcinolone acetonide. Adverse events were mainly mild to moderate, with infections of the upper respiratory tract and nasopharyngitis being the most frequent.

Ilaris, developed by Novartis, is administered in a single, subcutaneous injection of 150 mg. This is the first biologic approved by the European Commission for a gouty arthritis indication. The EC also granted an additional year of data exclusivity to Novartis based on the significant clinical benefit over existing treatments demonstrated for Ilaris.

"The approval of Ilaris for acute gouty arthritis attacks in patients without appropriate treatment options provides new hope for those debilitated by this excruciating condition," said David Epstein, division head of Novartis, in a press release. "Ilaris targets interleukin-1 beta, a key player in gouty arthritis inflammation. Our vision is to realize the potential of Ilaris wherever IL-1 beta plays a key role and available treatment options don't give patients the help they need."

Gouty arthritis, commonly known as gout, is a serious, chronic and progressive inflammatory disease affecting 1 to 4% of adults. Gouty arthritis attacks occur when the body produces a strong inflammatory response to uric acid crystals forming in the affected joints of the toe, foot, ankle, or knee. This disease is associated with a high prevalence of comorbidities, including hypertension, kidney disease, diabetes, dyslipidemia and cardiovascular disease, which can consequently lead to contraindications for existing therapies and complications for disease management.

Ilaris, the only approved fully human monoclonal antibody targeting IL-1 beta, is being investigated in a number of rare inflammatory conditions, including systemic juvenile idiopathic arthritis (SJIA), tumor necrosis factor receptor-associated periodic syndrome (TRAPS), colchicine-resistant familial Mediterranean fever (FMF), and cardiovascular disease. The agent has been approved in more than 60 countries, including in the EU, US, Switzerland and Japan for the treatment of cryopyrin-associated periodic syndromes (CAPS).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here